Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials
Authors:
- 1 February 2014
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 14 (2) , 119-129
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: A cluster randomized trial in Karachi, PakistanVaccine, 2012
- Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy AdultsPLOS ONE, 2011
- The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant VaccinesClinical and Vaccine Immunology, 2011
- Burden of typhoid and paratyphoid fever in a densely populated urban community, Dhaka, BangladeshInternational Journal of Infectious Diseases, 2010
- A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in IndiaNew England Journal of Medicine, 2009
- a study of typhoid fever in five Asian countries: disease burden and implications for controlsBulletin of the World Health Organization, 2008
- Typhoid fever in children: some epidemiological considerations from Karachi, PakistanInternational Journal of Infectious Diseases, 2006
- Bacteremic Typhoid Fever in Children in an Urban Slum, BangladeshEmerging Infectious Diseases, 2005
- The Efficacy of aSalmonella typhiVi Conjugate Vaccine in Two-to-Five-Year-Old ChildrenNew England Journal of Medicine, 2001